Oxybate-PEG Ester Prodrugs for Narcolepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium oxybate formulations for treating narcolepsy and cataplexy are limited by high sodium content, leading to compliance issues, toxicity risks, and abuse potential due to rapid absorption and short elimination half-life, as well as instability and misusage challenges.
Innovation Solution
Development of oxybate-polyethylene glycol (PEG) ester prodrugs and conjugates, including oxybate-PEG-cyclodextrin double cleavage prodrugs and anion exchange resin complexes, which provide a sodium-free, abuse-resistant, and stable formulation with extended release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium oxybate is administered to achieve rapid absorption and effective plasma levels, then therapeutic effect is improved, but toxicity risk increases due to high Cmax
Solution Approach 1:
The patent applies preliminary action by converting oxybate into a prodrug form (e.g., oxybate-PEG conjugates or oxybate salts with modified release properties) before administration. This pre-modification allows the drug to be released gradually in the body, preventing the sudden high Cmax that causes toxicity while still achieving effective plasma levels over time. The prodrug structure is designed to undergo controlled conversion to the active oxybate form.
Solution Approach 2:
The patent changes the physical and chemical parameters of oxybate by forming conjugates with polyethylene glycol (PEG) or using alternative salts. These parameter changes modify the drug's solubility, molecular weight, and release characteristics, transforming it from a rapidly absorbed form to one with extended release properties, thereby reducing peak concentration and associated toxicity.
2Duration of action of moving object
If high dose sodium oxybate is administered to maintain effective plasma levels throughout dosing interval, then duration of action is improved, but patient compliance deteriorates due to need for divided doses
Solution Approach 1:
The patent uses preliminary action by formulating oxybate as a prodrug with built-in controlled release mechanisms. The oxybate-PEG conjugates or modified salt forms are designed to release the active drug over an extended period, allowing single-dose administration that maintains effective plasma levels throughout the night without requiring patients to wake up for divided doses.
Solution Approach 2:
The patent achieves continuity of useful action through extended-release formulations that maintain steady plasma concentrations of oxybate throughout the dosing interval. The controlled release mechanism ensures continuous therapeutic effect without interruption, eliminating the need for divided doses and improving patient compliance.
3Speed
If sodium salt of oxybate is used to ensure sufficient solubility in acidic media, then absorption rate is improved, but harmful factors increase due to high sodium content
Solution Approach 1:
The patent introduces an intermediary substance (polyethylene glycol or alternative cations) to replace sodium in the oxybate salt structure. The oxybate-PEG conjugate acts as an intermediary that provides sufficient solubility in acidic gastric media without relying on sodium ions, thereby maintaining absorption rate while eliminating the harmful effects of high sodium content.
Solution Approach 2:
The patent changes the ionic composition parameter of oxybate by replacing sodium with alternative cations or using non-ionic PEG conjugates. This parameter change maintains the solubility needed for rapid absorption in acidic media while eliminating the high sodium content that poses health risks to patients with cardiovascular or renal conditions.
4Reliability
If oxybate is administered to achieve rapid absorption from upper GI tract, then therapeutic effect is improved, but abuse potential increases due to common metabolic pathway with alcohol
Solution Approach 1:
The patent applies preliminary action by converting oxybate into a prodrug form that undergoes controlled metabolic conversion in the body. The oxybate-PEG conjugates or modified salts are metabolized more slowly and through different pathways compared to direct oxybate administration, reducing the competition with alcohol metabolism and lowering abuse potential while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oxybate-PEG ester prodrugs offer improved patient compliance, reduced toxicity, enhanced stability, and prolonged plasma detection, addressing the limitations of existing sodium oxybate formulations by providing a once-a-night long-acting formulation suitable for patients with sodium restrictions and reducing abuse potential.
Implementation Method 1
oxybate-polyethylene glycol (PEG) ester prodrugs
Implementation Method 2
anion exchange resin complexes
Data Source
AI summary
Oxybate-PEG ester prodrugs are provided herein in which the polyethylene glycol is bound to oxybate via an ester linkage. These oxybate-PEG esters may be further bound to a cyclodextrin or an anion exchange resin, via an ester linkage between the oxybate and the cyclodextrin or via ionic bonding between oxybate the anion exchange resin. Compounds and compositions containing these compounds are useful in immediate release and modified release compositions for treating narcolepsy and other disorders.